Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gene therapy |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XL10
|
| gptkbp:brand |
gptkb:Carvykti
|
| gptkbp:developer |
gptkb:Janssen
gptkb:Legend_Biotech |
| gptkbp:genericName |
gptkb:ciltacabtagene_autoleucel
|
| https://www.w3.org/2000/01/rdf-schema#label |
cilta-cel
|
| gptkbp:indication |
multiple myeloma
|
| gptkbp:mechanismOfAction |
genetically modified autologous T cells express a chimeric antigen receptor targeting BCMA
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
infections
neurotoxicity cytokine release syndrome cytopenias |
| gptkbp:source |
autologous T cells
|
| gptkbp:storage |
frozen
|
| gptkbp:target |
gptkb:BCMA
|
| gptkbp:treatment |
immunotherapy
gene therapy |
| gptkbp:bfsParent |
gptkb:Legend_Biotech
|
| gptkbp:bfsLayer |
7
|